Eyepoint Pharmaceuticals Stock News

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) has earned a consensus recommendation of Buy from the five analysts that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 1 year price target among analysts that have updated their coverage []

EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) shares, rose in value on Wednesday, 11/24/21, with the stock price down by -3.63% to the previous days close as strong demand from buyers drove the stock to $16.71. Actively observing the price movement in the last trading, the stock closed the session at $17.34, falling within a range of $16.64 EyePoint Pharmaceuticals Inc. (NASDAQ: EYPT): A Great Stock To Watch Read More »

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) has earned an average rating of Buy from the five ratings firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average twelve-month price objective among brokerages that have updated []

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)s share price gapped down before the market opened on Thursday . The stock had previously closed at $18.40, but opened at $17.33. EyePoint Pharmaceuticals shares last traded at $17.60, with a volume of 4,170 shares. Several research analysts recently issued reports on the stock. Cowen raised their target price on shares []

WATERTOWN, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the closing of the previously announced underwritten public offering of 5,122,273 shares of its common stock, which included the exercise in full by the underwriters of their option to purchase an additional 1,095,000 shares of common stock, and pre-funded warrants to purchase up to an aggregate of 3,272,727 shares of its common stock. The shares of common stock were sold at a public offering price of $13.75 per share, and the pre-funded warrants were sold at a purchase price of $13.74 per pre-funded warrant, for aggregate gross proceeds of approximately $115.4 million, before deducting underwriting discounts and commissions and other offering expenses payable by EyePoint. All of the securities were sold by EyePoint.

EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) price on Thursday, November 18, fall -10.92% below its previous days close as a downside momentum from buyers pushed the stocks value to $16.39. A look at the stocks price movement, the close in the last trading session was $18.40. The beta value (5-Year monthly) was 1.35. Turning to its 52-week EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) Shares In 2021: Bullish Prospects Read More »

EyePoint Pharmaceuticals (NASDAQ:EYPT) had its price target upped by Cowen from $25.00 to $35.00 in a research note published on Monday, The Fly reports. They currently have an outperform rating on the stock. Other research analysts have also recently issued reports about the stock. HC Wainwright reissued a buy rating and set a $24.00 target []

HC Wainwright reissued their buy rating on shares of EyePoint Pharmaceuticals (NASDAQ:EYPT) in a research report report published on Monday, Price Targets.com reports. The firm currently has a $24.00 target price on the stock, up from their previous target price of $15.00. Separately, Zacks Investment Research lowered shares of EyePoint Pharmaceuticals from a hold rating […]

The eyecare specialist has good momentum behind it as it prices a new round of capital raising.

The shares of Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) increased by over 30% during intraday trading today. This is why it happened.

Vanguard Group Inc. boosted its stake in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 20.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,086,329 shares of the companys stock after acquiring an additional 181,890 shares during the quarter. Vanguard Group []

EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) has priced an underwritten public offering of 4.03 million at $13.75 per share and pre-funded warrants to purchase up to an aggregate of 3.27 million sha